Novo Nordisk

0:13:20

The Novo Nordisk scientist behind Ozempic, Wegovy weight loss research

0:05:48

With Novo Nordisk success, is there a 'Nokia risk' for Denmark?

0:00:29

The Land Of Novo I Sunday on 60 Minutes

0:02:16

How Novo Nordisk built an empire selling diabetes and weight-loss drugs

0:04:29

NBC News Exclusive: Ozempic and Wegovy Novo Nordisk CEO speaks out on high prices, drug shortages

0:01:55

Novo Nordisk CEO testifies before Senate on weight loss drug prices

3:45:26

Novo Nordisk (Ozempic)

0:04:34

Earnings Exchange: Supermicro, Novo Nordisk, CVS Health

0:03:26

TIME100 Most Influential Companies: Novo Nordisk

0:00:55

The Novo Nordisk Corporate Structure

0:19:20

How Ozempic And Wegovy Accidentally Made Novo Nordisk A $400B Company

0:09:39

Novo Nordisk CEO on Wegovy, Ozempic, Profit Forecast, US Market

0:04:35

Novo Nordisk shares sink on medicare price negotiation fears

0:01:56

Novo Nordisk Boss on Ozempic and Eating Disorder Criticism, Social Media Pressure

0:00:52

Ozempic Maker Novo Nordisk Has Denmark’s Economy Hooked

0:05:00

Novo Nordisk CEO defends high price off Ozempic and Wegovy

0:02:40

Why Novo Nordisk's corporate structure stands out

0:01:40

Life-changing careers at Novo Nordisk

0:05:26

Dr. Scot Gottlieb on Novo Nodrisk's oral diabetes drug, future of weight-loss drugs

0:24:07

The CEO Behind Ozempic, Wegovy and Europe's Most Valuable Company

2:15:10

Novo Nordisk CEO Lars Jorgensen testifies before Senate on weight loss drugs pricing — 9/24/24

0:02:53

Ozempic and Wegovy drugmaker CEO defends high costs of drugs

0:01:08

Introduction to Novo Nordisk's Graduate Programme

0:01:40

Life-changing careers bei Novo Nordisk